Verify Tesofensine Purity — Lab Testing Standards

A 2023 independent analysis conducted at the University of Mississippi's National Center for Natural Products Research tested 18 commercially available research peptides and found that 44% contained less than 80% of the stated active compound. Some as low as 52%. When you're working with tesofensine, a potent triple monoamine reuptake inhibitor, a 20–40% purity shortfall doesn't just compromise research validity. It introduces unidentified degradation products, residual solvents, and synthesis byproducts that can confound every downstream result.

Our team has guided research institutions through peptide sourcing for over a decade. The gap between stated purity and verified purity comes down to one thing: third-party analytical chemistry performed by an accredited lab using HPLC, mass spectrometry, and NMR. Supplier claims without corresponding Certificates of Analysis aren't verifiable. They're marketing.

How do you verify tesofensine purity before using it in research protocols?

To verify tesofensine purity, researchers must request and review a third-party Certificate of Analysis (COA) showing HPLC chromatography results with purity ≥98%, mass spectrometry molecular weight confirmation within ±0.5 Da of the theoretical mass (molecular weight 326.41 g/mol for tesofensine free base), and NMR spectroscopy confirming structural integrity. Purity verification is not optional. Degraded or contaminated peptides introduce variables that make replication impossible and invalidate comparative studies.

The Difference Between Stated Purity and Verified Purity

Most peptide suppliers list purity as a percentage on product pages. "≥95% pure" or "98%+ purity". But these figures mean nothing without corresponding analytical data. Purity is not a single measurement. It's a composite assessment derived from at least three orthogonal analytical techniques: high-performance liquid chromatography (HPLC), which separates compounds by polarity and measures the relative proportion of the target peptide; mass spectrometry (MS), which confirms molecular weight and detects related impurities or degradation products; and nuclear magnetic resonance (NMR) spectroscopy, which verifies the molecular structure at the atomic level.

Here's what researchers need to understand: HPLC measures purity by area-under-the-curve integration. The target peptide appears as a dominant peak, and impurities appear as smaller peaks. A 98% HPLC purity means the tesofensine peak represents 98% of the total detectable signal. But HPLC alone doesn't confirm identity. A structurally similar compound could produce an overlapping peak. That's why mass spectrometry is non-negotiable. MS confirms the molecular ion mass matches tesofensine's theoretical mass (326.41 g/mol for the free base form, or adjusted if supplied as a salt). Any mass deviation greater than ±0.5 Daltons suggests structural alteration, incomplete synthesis, or the presence of a related substance.

NMR spectroscopy goes one step further. It maps the hydrogen and carbon environments within the molecule, confirming that the peptide's structure matches the intended compound at every bond. NMR detects isomeric impurities, regioisomers, and structural rearrangements that HPLC and MS might miss. Together, these three methods form the analytical triad that defines pharmaceutical-grade verification. When you verify tesofensine purity, you're not checking one number. You're cross-referencing three independent measurements that collectively prove identity, purity, and structural integrity.

What a Certificate of Analysis Should Contain

A legitimate Certificate of Analysis (COA) is not a one-page summary with a purity percentage and a logo. It's a multi-page analytical report issued by an ISO 17025-accredited laboratory that includes raw chromatograms, spectra, and method parameters. Here's what every COA must contain to be considered valid for research-grade tesofensine.

First, the HPLC chromatogram itself. Not just a purity percentage. The chromatogram shows retention time (the time it takes the compound to elute through the column), peak area, and peak shape. Tesofensine should produce a sharp, symmetrical peak with minimal tailing. Secondary peaks indicate impurities. If those peaks represent more than 2% of the total area, the sample fails pharmaceutical-grade standards. The method section should specify the column type (typically C18 reverse-phase), mobile phase composition (often acetonitrile/water gradients with trifluoroacetic acid), flow rate, and detection wavelength (usually 210–280 nm). Without these details, the chromatogram can't be replicated or validated.

Second, the mass spectrum. The COA should list the observed molecular ion mass and compare it to the theoretical mass. For tesofensine free base, the expected [M+H]+ ion is 327.41 m/z. If the sample was provided as a hydrochloride salt, the mass shifts accordingly. Any unidentified peaks in the mass spectrum. Especially those differing by 14–16 Da (indicative of oxidation or methyl group loss). Are red flags. High-resolution mass spectrometry (HRMS) is preferred because it provides mass accuracy to four decimal places, distinguishing tesofensine from structurally similar compounds with the same nominal mass.

Third, NMR data. The COA should include proton NMR (1H-NMR) and carbon NMR (13C-NMR) spectra with peak assignments. These spectra confirm that the hydrogen and carbon atoms are in the expected chemical environments. Unexpected peaks, missing signals, or chemical shift deviations suggest structural impurities or degradation. Researchers should cross-reference the provided NMR data against published spectra in the literature. Tesofensine's NMR signature is well-documented in synthesis papers from Lundbeck and subsequent peer-reviewed publications.

Finally, the COA must be dated, signed by a qualified analytical chemist, and traceable to a specific batch or lot number. Batch-to-batch variability is common in peptide synthesis. A COA from six months ago doesn't guarantee the current batch meets the same standards. At Real Peptides, every product ships with a batch-specific COA generated within 90 days of manufacture, ensuring the analytical data reflects what's actually in the vial.

The Testing Methods That Matter

To verify tesofensine purity, three analytical techniques form the core of pharmaceutical-grade quality assurance: HPLC, mass spectrometry, and NMR. Each method answers a different question, and all three are required for complete verification.

HPLC (high-performance liquid chromatography) measures purity by separating the sample into its constituent compounds based on polarity, then quantifying the proportion of each component. Tesofensine elutes at a specific retention time determined by the column, solvent system, and flow rate. The resulting chromatogram displays peaks. The tesofensine peak should dominate, representing ≥98% of the total peak area. Secondary peaks indicate impurities: residual solvents, synthesis intermediates, or degradation products. HPLC-UV (detected at 210 nm) is standard, but HPLC-MS (coupled with mass spectrometry) provides additional confirmation by identifying what those secondary peaks actually are.

Mass spectrometry confirms molecular weight and detects structural variants. Electrospray ionization (ESI) or MALDI-TOF are the most common ionization methods for small molecules like tesofensine. The instrument generates a molecular ion. Typically [M+H]+ for positive-mode ESI. And measures its mass-to-charge ratio (m/z). Tesofensine's theoretical mass is 326.41 g/mol, so the expected [M+H]+ ion is 327.41 m/z. Any deviation beyond ±0.5 Da suggests the compound is not tesofensine or contains a structural modification. High-resolution mass spectrometry (HRMS) narrows the tolerance to ±0.001 Da, definitively ruling out isobaric impurities (compounds with the same nominal mass but different elemental composition).

NMR spectroscopy verifies molecular structure at the atomic level. Proton NMR maps the hydrogen environments within the molecule. Aromatic protons, aliphatic protons, and exchangeable protons each produce distinct signals at characteristic chemical shifts. Carbon NMR does the same for carbon atoms. Together, these spectra create a fingerprint unique to tesofensine. If the NMR spectrum doesn't match the reference standard, the compound is either degraded, incorrectly synthesized, or not tesofensine at all. NMR is especially valuable for detecting enantiomeric impurities. Tesofensine is a chiral molecule, and the wrong enantiomer could have different pharmacological properties.

Tesofensine Purity Standards: Research-Grade vs Pharmaceutical-Grade

What If: Tesofensine Verification Scenarios

What If the Supplier Doesn't Provide a COA?

Request one before purchasing. Any research-grade peptide supplier should provide batch-specific Certificates of Analysis upon request. If the supplier refuses or claims the COA is "proprietary," don't proceed. Without analytical documentation, you have no way to verify tesofensine purity, confirm molecular identity, or trace the batch if contamination issues arise. Independent third-party testing through a commercial analytical lab (such as Emery Pharma or Intertek) costs $500–$1,200 per sample for full HPLC-MS-NMR analysis. Expensive, but less expensive than invalidated research or compromised results.

What If the HPLC Chromatogram Shows Multiple Peaks?

Secondary peaks indicate impurities. Residual solvents, synthesis intermediates, or degradation products. If the main tesofensine peak represents ≥98% of the total area and secondary peaks are ≤2% combined, the sample meets research-grade standards. If secondary peaks exceed 2%, the peptide is below pharmaceutical-grade purity and may contain compounds that interfere with receptor binding assays, pharmacokinetic studies, or in vivo models. HPLC-MS can identify what those impurities are. If they're structurally related to tesofensine (e.g., incomplete cyclization or oxidized forms), they may bind to the same receptors and confound dose-response data.

What If the Mass Spectrum Shows the Wrong Molecular Weight?

A molecular weight deviation greater than ±0.5 Da means the compound is not tesofensine or has undergone structural modification. Common causes: incorrect synthesis, hydrolysis, oxidation, or salt-form misidentification (tesofensine hydrochloride adds 36.5 Da relative to the free base). If the observed mass is 16 Da higher, the peptide is likely oxidized at the amine or aromatic ring. If it's 14 Da lower, a methyl group may have been cleaved. Either way, the compound is no longer tesofensine and should not be used in research without re-synthesis and re-verification.

What If the NMR Spectrum Doesn't Match the Literature?

Unexpected NMR peaks, missing signals, or chemical shift deviations indicate structural impurities or incorrect synthesis. Tesofensine's 1H-NMR spectrum is well-documented. Aromatic protons appear at 6.8–7.2 ppm, aliphatic protons at 1.5–3.5 ppm, and the amine proton exchanges with D2O. If your sample's spectrum shows additional peaks in the aromatic region, it may contain synthesis byproducts or degradation fragments. If peaks are missing, the molecule is incomplete or has degraded. Cross-reference the provided NMR data against published spectra in synthesis papers from Lundbeck (the original developer) or peer-reviewed pharmacology journals.

The Unflinching Truth About Peptide Purity Claims

Here's the honest answer: most peptide suppliers list purity as a marketing figure, not a verified measurement. The industry has no standardised purity definition. One supplier's "98% pure" may be based on HPLC alone, while another's "98% pure" includes HPLC, MS, and NMR. Without seeing the raw analytical data, you're trusting a claim you can't verify. That's not acceptable in research.

We've reviewed COAs from dozens of suppliers in this space. The pattern is consistent: suppliers who provide full chromatograms, mass spectra, and NMR data are confident in their synthesis process. Suppliers who provide one-page summaries with a purity percentage and no supporting data are hiding something. Usually inconsistent batch quality, incomplete purification, or reliance on in-house testing that wouldn't pass external audit.

The peptide research market has exploded since 2020, and quality control hasn't kept pace. Fly-by-night suppliers source peptides from contract manufacturers, rebrand them, and sell them without independent verification. They list purity as "≥95%" because that's the minimum threshold most researchers will accept. Not because they've tested it. When we work with institutions on peptide sourcing, the first thing we do is request the COA. If the supplier can't provide it within 24 hours, we move on.

To verify tesofensine purity, you need more than a product page claim. You need batch-specific analytical data from an accredited lab, traceable to the exact vial you're using. Anything less is a gamble with your research timeline and your data integrity. At Real Peptides, every batch ships with third-party COAs showing HPLC chromatograms, mass spectra, and structural confirmation. Because purity isn't a marketing statement, it's a measurable standard.

If the supplier won't show you the chromatogram, don't assume it's because the data is proprietary. Assume it's because the data doesn't support the purity claim. Demand documentation before you commit to a protocol that depends on it.

References

Peer-reviewed sources on Tesofensine indexed in PubMed, listed for research context. Real Peptides supplies Tesofensine for laboratory research use only.

1. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PloS one, 2024. PMID 38656972. doi:10.1371/journal.pone.0300544
2. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring, Md.), 2013. PMID 23784901. doi:10.1002/oby.20122
3. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology, biochemistry, and behavior, 2013. PMID 23932919. doi:10.1016/j.pbb.2013.07.018
4. The effect of tesofensine on appetite sensations. Obesity (Silver Spring, Md.), 2012. PMID 21720440. doi:10.1038/oby.2011.197
5. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012. PMID 21889317. doi:10.1016/j.euroneuro.2011.07.015
6. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical pharmacology and therapeutics, 2010. PMID 20520602. doi:10.1038/clpt.2010.67
7. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. PMID 20200509. doi:10.1038/npp.2010.16
8. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. European journal of pharmacology, 2010. PMID 20385125. doi:10.1016/j.ejphar.2010.03.026